IL152671A0 - Hcv variants - Google Patents

Hcv variants

Info

Publication number
IL152671A0
IL152671A0 IL15267101A IL15267101A IL152671A0 IL 152671 A0 IL152671 A0 IL 152671A0 IL 15267101 A IL15267101 A IL 15267101A IL 15267101 A IL15267101 A IL 15267101A IL 152671 A0 IL152671 A0 IL 152671A0
Authority
IL
Israel
Prior art keywords
hcv
variants
methods
expression vectors
polynucleotides
Prior art date
Application number
IL15267101A
Other languages
English (en)
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/576,989 external-priority patent/US7049428B1/en
Application filed by Univ Washington filed Critical Univ Washington
Publication of IL152671A0 publication Critical patent/IL152671A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
IL15267101A 2000-05-23 2001-05-23 Hcv variants IL152671A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/576,989 US7049428B1 (en) 1998-03-04 2000-05-23 HCV variants
PCT/US2001/016822 WO2001089364A2 (en) 2000-05-23 2001-05-23 Hcv variants

Publications (1)

Publication Number Publication Date
IL152671A0 true IL152671A0 (en) 2003-06-24

Family

ID=24306833

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15267101A IL152671A0 (en) 2000-05-23 2001-05-23 Hcv variants
IL152671A IL152671A (en) 2000-05-23 2002-11-06 Polynucleotide comprising a non - naturally occurring hcv sequence that is capable of productive replication in a host cell, vectors, cells and a method for identifying cell line permissive for infection with hcv
IL176731A IL176731A (en) 2000-05-23 2006-07-06 Method for producing a cell line permissive for hcv replication and a cell line produced by said method

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL152671A IL152671A (en) 2000-05-23 2002-11-06 Polynucleotide comprising a non - naturally occurring hcv sequence that is capable of productive replication in a host cell, vectors, cells and a method for identifying cell line permissive for infection with hcv
IL176731A IL176731A (en) 2000-05-23 2006-07-06 Method for producing a cell line permissive for hcv replication and a cell line produced by said method

Country Status (9)

Country Link
EP (1) EP1296998B1 (enExample)
JP (2) JP4095303B2 (enExample)
AT (1) ATE525384T1 (enExample)
AU (1) AU2001263407B9 (enExample)
CA (1) CA2409873C (enExample)
DK (1) DK1296998T3 (enExample)
ES (1) ES2373642T3 (enExample)
IL (3) IL152671A0 (enExample)
WO (1) WO2001089364A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
ES2287074T3 (es) * 2000-12-22 2007-12-16 Boehringer Ingelheim (Canada) Ltd. Molecula de rna autorreplicante del virus de la hepatitis c.
EP2050822B1 (en) * 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C virus replicons and replicon enhanced cells
ES2321498T3 (es) * 2002-03-11 2009-06-08 Lab 21 Limited Metodos y composiciones para identificar y caracterizar la hepatitis c.
ATE426682T1 (de) * 2002-04-16 2009-04-15 Merck & Co Inc Hepatitis-c-virus-testsysteme
KR100502864B1 (ko) * 2002-10-09 2005-07-22 (주)팬바이오넷 Ｃ형 간염바이러스의 복제 정량 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 ｈｃｖ 저해제의 탐색방법
CA2505551A1 (en) * 2002-11-13 2004-05-27 Washington University Highly permissive cell lines for hepatitis c virus replication
DE602004024658D1 (de) 2003-02-13 2010-01-28 Merck & Co Inc Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
JP4342519B2 (ja) * 2003-09-22 2009-10-14 株式会社グリーンペプタイド Ｃ型肝炎ウイルス由来ペプチド
EP1685238A4 (en) 2003-11-05 2008-08-20 Merck & Co Inc HCV REPLICONS WITH NS5B GENOTYP 2B
KR100894150B1 (ko) * 2004-06-25 2009-04-22 가부시끼가이샤 센단세메이가가꾸겐큐죠 신규한 배열을 가진 ｈｃｖ ｒｎａ
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
CN101688197A (zh) * 2007-04-27 2010-03-31 株式会社先端生命科学研究所 Hcv基因
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009079185A2 (en) * 2007-11-26 2009-06-25 Novartis Vaccines And Diagnostics, Inc. Methods of generating alphavirus particles
EP2558117A4 (en) * 2010-04-12 2013-11-13 Viracine Therapeutics Corp EXPRESSION OF POSITIVELY SENSING INTRODUCING RNA VIRUSES AND USES THEREOF
EP2917340A1 (en) 2012-11-07 2015-09-16 Gilead Sciences, Inc. Hcv genotype 6 replicons
CN112225783B (zh) * 2020-09-16 2021-08-31 东莞市朋志生物科技有限公司 Hcv重组抗原及其突变体

Also Published As

Publication number Publication date
JP2007143553A (ja) 2007-06-14
AU6340701A (en) 2001-12-03
WO2001089364A9 (en) 2003-07-10
IL176731A0 (en) 2006-10-31
CA2409873C (en) 2013-01-08
JP4095303B2 (ja) 2008-06-04
CA2409873A1 (en) 2001-11-29
WO2001089364A2 (en) 2001-11-29
EP1296998B1 (en) 2011-09-21
JP2003533232A (ja) 2003-11-11
AU2001263407B9 (en) 2007-05-24
ATE525384T1 (de) 2011-10-15
DK1296998T3 (da) 2011-12-12
WO2001089364A3 (en) 2003-01-23
EP1296998A4 (en) 2009-01-28
AU2001263407B2 (en) 2006-12-07
ES2373642T3 (es) 2012-02-07
IL152671A (en) 2009-09-01
EP1296998A2 (en) 2003-04-02
IL176731A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
AU6340701A (en) Hcv variants
AU5022101A (en) Formulations and methods of using nitric oxide mimetics against a malignant cellphenotype
ES2020152A4 (es) Diagnosticos y vacunas para nanbv.
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
AU4203201A (en) Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
WO2003104411A3 (en) BIOARTIFICIAL LIVER SYSTEM
MXPA03001622A (es) Peptidos que atraviesan membranas y sus usos.
GB9925955D0 (en) Hcv n33 protease inhibitors
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
ZA852564B (en) Live purified marek's disease vaccine
GB0224000D0 (en) Herpes viruses for immune modulation
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
AP2000001892A0 (en) Self-replicating vector for DNA immunization against HIV.
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2001012215A3 (en) Protective antigen of Epstein barr virus
Boroń Replication banding patterns in the spined loach, Cobitis taenia L.(Pisces, Cobitidae)
CN212254483U (zh) 一种智能电压力锅性能测试装置
WO2001090302A3 (en) Compositions and methods for production of rna viruses and rna virus-based vector particles
TW200610539A (en) A preparation containing alkaline medicament
WO2004065408A3 (en) Enhancement of humoral immune responses using a novel myeloid accessory cell
PT1282710E (pt) Vacina contra a piscirickettsia salmonis para peixes
EP1161953A3 (en) IBDV strain for in OVO administration
ES2139549A1 (es) Vacuna anti-flexibacter maritimus (fm-95) para la prevencion de la enfermedad "flexibacteriosis marina" en rodaballo y peces salmonidos, y procedimiento de obtencion.
YIN et al. Effect of Cyclosporine A on stable established lymphoma models induced by Epstein-Barr virus
Bilandžija et al. Phylogenetic position of endangered stygobitic bivalve Congeria kusceri and phylogeographic structure in Croatia based on mitochondrial and nuclear DNA markers